Multisystem inflammatory syndrome in children (MIS-C) is a serious complication of SARS-CoV-2 infection.1 A previous study that described MIS-C cases in the first 3 waves of the COVID-19 pandemic found that the proportion of individuals with severe illness declined after the first wave.2 In Israel, the Omicron (B.1.1.529) variant started to spread […]
As a pediatric kidney doctor, Elaine S. Kamil, MD, is used to long hours helping children and teens with a variety of issues, some very serious, and also makes time to give back to her specialty. In late 2013, she was in Washington, DC, planning a meeting of the American […]
Decreased motor function, as well as other adverse outcomes, are linked to post-COVID-19 syndrome in patients with Parkinson’s disease (PD), new research suggests. Results from a small, international retrospective case study show that about half of participants with PD who developed post-COVID-19 syndrome experienced a worsening of motor symptoms and […]
BACKGROUND The assessment of real-world effectiveness of immunomodulatory medications for multisystem inflammatory syndrome in children (MIS-C) may guide therapy. METHODS We analyzed surveillance data on inpatients younger than 21 years of age who had MIS-C and were admitted to 1 of 58 U.S. hospitals between March 15 and October 31, […]
About half of children with pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) have new-onset neurologic symptoms, research shows. These symptoms involve the central and peripheral nervous systems but do not always affect the respiratory system. In addition, neurologic symptoms appear to be more common in severe presentations of […]
